Dario Paggiarino, Chief Medical Officer of EyePoint Pharmaceuticals Inc (EYPT, Financial), sold 16,386 shares of the company on January 24, 2024, according to a recent SEC Filing.
EyePoint Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapeutics for eye diseases. The company's pipeline includes treatments for conditions such as uveitis, diabetic macular edema, and other eye disorders.
Over the past year, the insider has sold a total of 71,382 shares and has not made any purchases of the company's stock.
The insider transaction history for EyePoint Pharmaceuticals Inc shows a pattern of insider activity. In the past year, there have been 3 insider buys and 19 insider sells.
On the day of the insider's recent sell, shares of EyePoint Pharmaceuticals Inc were trading at $25.01, giving the company a market cap of $1.216 billion.
The stock's price-to-GF-Value ratio stands at 4.25, with a GuruFocus Value of $5.88, indicating that EyePoint Pharmaceuticals Inc is significantly overvalued based on its GF Value.
The GF Value is calculated considering historical trading multiples, a GuruFocus adjustment factor based on the company's historical returns and growth, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
